CanSino Biologics Gets China Trial Approval to Expand Vaccine's Booster Age Range

MT Newswires Live
昨天

CanSino Biologics (HKG:6185) received approval from China's National Medical Products Administration to begin a clinical trial of its Td5cp combined vaccine in children aged four to five, according to a Monday Hong Kong bourse filing.

The trial will assess whether the vaccine can be used as a booster in children aged four to six, extending its current booster-use age range, which starts at 6 years.

The vaccine is designed to protect against tetanus, diphtheria and pertussis, also known as whooping cough. The company said the proposed expansion aims to address a gap in preschool booster immunization and restore antibody levels to a protective range.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10